The past months have revealed a series of developments in the field of mental health, ranging from media-driven changes in public behaviour to new scientific findings in Europe and the United States. These updates highlight how cultural exposure, biomedical innovation and clinical evidence continue to shape psychiatric practice and patient engagement worldwide.

Media Exposure Linked to Increased Interest in Sedatives

In the United States, researchers observed a notable rise in online searches for lorazepam following the most recent season of the television series The White Lotus.
According to an analysis published in the JAMA Health Forum, the medication’s on-screen visibility was followed by a measurable surge in Google queries, suggesting once again that popular media can directly influence public awareness of psychotropic drugs.

New Neuromodulation Options for Severe Depression in Young People

The U.S. Food and Drug Administration (FDA) expanded the approved use of the BrainsWay Deep Transcranial Magnetic Stimulation system.
This device may now be used as an adjunctive therapy in individuals aged 15 to 21 years diagnosed with major depressive disorder.
The decision reflects the growing interest in non-invasive neuromodulation, particularly for young patients who have not achieved adequate response to standard antidepressant treatments.

Deep Brain Stimulation Shows Promise in Resistant Depression

A small but significant investigation, reported in Nature Communications, assessed deep brain stimulation (DBS) targeting the bed nucleus of the stria terminalis and the nucleus accumbens.
Among adults with treatment-resistant depression, researchers documented a 50% response rate and 35% remission rate, demonstrating that DBS may offer meaningful benefits when conventional therapies fail.

Experimental Cognitive Enhancer Falls Short in Phase III Trials

In contrast to the above findings, an investigational glycine transporter-1 inhibitor, iclepertin, failed to improve cognitive outcomes in adults with schizophrenia during three late-stage trials.
The results, published in Lancet Psychiatry, indicate that the long-anticipated class of glutamatergic-based cognition enhancers remains challenging to translate into clinical benefit.

Public Figures Continue to Destigmatise Psychiatric Treatment

In the United States, singer and actress Lady Gaga publicly discussed her experiences with lithium therapy during the filming of A Star Is Born.
As reported by international media, she noted that she later experienced a psychotic episode, bringing further public attention to the complexity of mood-stabiliser management.
Such disclosures contribute to ongoing global conversations about the realities of psychiatric treatment.

Light-Based Therapies Remain Relevant for Seasonal Depression

Experts interviewed by The New York Times reaffirmed that specialised light boxes designed for Seasonal Affective Disorder (SAD) can offer relief for individuals experiencing recurrent winter-linked low mood.
While not a replacement for clinical care, the intervention remains one of the most recognised non-pharmacological strategies for seasonal depression.

GLP-1 Agonists Show Additional Benefits Beyond Weight Control

A meta-analysis reviewing 14 studies, published in eClinicalMedicine, revealed that GLP-1 receptor agonists—including semaglutide and liraglutide—may reduce alcohol consumption, help prevent relapse, and improve alcohol-related morbidity.
Although primarily prescribed for metabolic disorders, these agents may hold unexpected value in addiction-related pathways.

Early Evidence Suggests Microdosing LSD May Be Safe Under Controlled Conditions

A small open-label study involving 19 participants, reported in Neuropharmacology, provided preliminary evidence that microdosing lysergic acid diethylamide (LSD) at home may be feasible and generally safe when conducted within strict research protocols.
The findings remain early-stage but add to the growing scientific interest in psychedelic-based mental-health interventions.

Higher Suicide Risk in Veterans With Post-Traumatic Headache

In the Americas, a study published in Lancet Regional Health – Americas found that military veterans experiencing post-traumatic headaches had significantly higher rates of suicidal ideation and attempts compared with those who sustained a traumatic brain injury without subsequent headache.
The results underscore the importance of proper neurological and psychiatric follow-up in this vulnerable population.

Digital Mental-Health Applications Show High Engagement but Moderate Long-Term Use

A comprehensive review of 79 randomised trials, presented in JAMA Psychiatry, found that digital mental-health applications for depression and anxiety reached an adherence rate of 92.4%, but actual long-term use averaged 61.8%.
These findings reflect the ongoing challenge of maintaining patient engagement with digital therapeutics despite initial interest.